Delayed launch readiness
Two in three biotech launches underperform forecast.*
Senior Commercial and Launch Leadership for Emerging Biotech
Helping biotech companies bring science to patients.
Guiding teams from clinical development through first commercial launch and lifecycle management.
25+Years in biopharma commercialization
U.S. + GlobalLaunch and lifecycle leadership
Oncology + Rare Oncology + SpecialtyDeep category experience
The launch reality
More than 65% of first-time launches fail to meet expectations.*
The core launch risks for first-time biotechs
Market access delays & strategy misalignment
Coverage barriers and late access planning can slow patient starts and early uptake.
Execution gap
Without early governance and cross-functional alignment, execution risk builds before market entry.
*Statistics sourced from McKinsey (2026) and IQVIA (2026).
A different advisory model
First-time launchers need a different advisory model.
Advice grounded in real-world launch experience.
Right-sized structure
Built to Scale
Offering the advantages of agility without the complexity or overhead of a larger firm.
Flexible by design
Bespoke Support
Focused support that flexes as priorities, risks, and execution needs evolve.
Decision intelligence
Scientific Modeling
Decision-ready analytics and modeling that sharpen commercial choices, investment priorities, and launch performance—including customer segmentation and geographic targeting.
People behind the work
Meet the team.
Beyond our core team, Olmo Group brings together a broad, trusted network of seasoned launch specialists with deep expertise across the commercialization journey.
kendalee.olmo@olmogroupbio.com
Kendalee Olmo
Founder, Commercial Excellence & Launch Strategy
Senior biopharma commercial leader with 20+ years in oncology and specialty care, including U.S. and global blockbuster launches from pipeline to market. At BMS, Sanofi, Pfizer, and Teva, she served on senior launch leadership teams, guiding commercial priorities, investment, portfolio and lifecycle strategy, and managing brands across every budget scale.
Luke Rhodes, MPH
Data Scientist
Oxford University-trained applied health data scientist and technology leader building businesses from the ground up. His expertise includes EHR interoperability, FHIR/SMART on FHIR, health information exchange, longitudinal records, and AI-supported clinical workflows. Experience spans clinical risk modelling, external validation, and deployment-ready decision tools.
Monyrath (Mony) Chan, MS, MBA
Launch & Market Development
Pharmaceutical leader with 10+ years spanning scientific research, commercial strategy, and HCP marketing at Sanofi, Pfizer, and EMD Serono, among others. Grounded in drug development, he bridges science and business to guide product launches and market development across rare disease, neurology, oncology, and cardiology.
Find your best starting point
What does your launch need right now?
Choose your stage and most pressing need. We’ll match it to the Olmo Group support that can create the most immediate value.
01
Where are you in the journey?
02
What is the most pressing need?
Your recommended starting pointBEST FIT
Senior Launch Advisory
Build the commercial path before the launch plan hardens.
Align the strategic choices, label scenarios, and near-term priorities that will shape downstream investment and readiness.